Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:CFRX NASDAQ:OVID NASDAQ:TYME NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.71+0.0%$0.73$0.17▼$2.63$2.26M0.04138,208 shs1,578 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsOVIDOvid Therapeutics$1.63+4.5%$1.37$0.24▼$2.01$115.91M0.355.57 million shs1.43 million shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsVSTMVerastem$7.95+1.8%$9.03$3.17▼$11.24$489.28M0.892.06 million shs1.63 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%-2.71%-21.03%+78.83%-66.18%CFRXContraFect0.00%0.00%0.00%0.00%0.00%OVIDOvid Therapeutics0.00%+10.14%+15.60%+163.54%+35.83%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%VSTMVerastem0.00%-13.77%-7.67%+29.48%+142.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.71+0.0%$0.73$0.17▼$2.63$2.26M0.04138,208 shs1,578 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsOVIDOvid Therapeutics$1.63+4.5%$1.37$0.24▼$2.01$115.91M0.355.57 million shs1.43 million shsTYMETyme Technologies$0.31$0.30$0.22▼$1.14$53.51M0.931.01 million shs2.68 million shsVSTMVerastem$7.95+1.8%$9.03$3.17▼$11.24$489.28M0.892.06 million shs1.63 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics0.00%-2.71%-21.03%+78.83%-66.18%CFRXContraFect0.00%0.00%0.00%0.00%0.00%OVIDOvid Therapeutics0.00%+10.14%+15.60%+163.54%+35.83%TYMETyme Technologies0.00%0.00%0.00%0.00%0.00%VSTMVerastem0.00%-13.77%-7.67%+29.48%+142.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/ACFRXContraFect 0.00N/AN/AN/AOVIDOvid Therapeutics 2.86Moderate Buy$3.70126.99% UpsideTYMETyme Technologies 0.00N/AN/AN/AVSTMVerastem 3.00Buy$14.1477.90% UpsideCurrent Analyst Ratings BreakdownLatest CFRX, OVID, TYME, VSTM, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025OVIDOvid TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.0010/21/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.0010/20/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$13.0010/20/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/16/2025VSTMVerastemCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight10/10/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/9/2025OVIDOvid TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.0010/8/2025OVIDOvid TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ACFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AOVIDOvid Therapeutics$570K203.35N/AN/A$0.96 per share1.70TYMETyme TechnologiesN/AN/AN/AN/A$0.47 per shareN/AVSTMVerastem$10K48,924.30N/AN/A($0.65) per share-12.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.950.04∞N/AN/A-471.57%-296.50%11/12/2025 (Estimated)CFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AOVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)TYMETyme Technologies-$23.63M-$0.14N/A∞N/AN/A-28.30%-26.21%N/AVSTMVerastem-$130.64M-$3.28N/AN/AN/AN/AN/A-119.85%11/4/2025 (Estimated)Latest CFRX, OVID, TYME, VSTM, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025OVIDOvid Therapeutics-$0.15N/AN/AN/A$0.17 millionN/A11/4/2025Q3 2025VSTMVerastem-$0.71N/AN/AN/A$5.76 millionN/A8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACFRXContraFectN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ATYMETyme TechnologiesN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70CFRXContraFectN/A0.530.53OVIDOvid Therapeutics0.234.724.72TYMETyme TechnologiesN/A14.0614.06VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%CFRXContraFect7.85%OVIDOvid Therapeutics72.24%TYMETyme Technologies16.69%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%CFRXContraFect0.62%OVIDOvid Therapeutics13.10%TYMETyme Technologies16.90%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableCFRXContraFect2310.70 million10.64 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableTYMETyme Technologies17172.21 million143.10 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableCFRX, OVID, TYME, VSTM, and ATXI HeadlinesRecent News About These CompaniesWeiss Ratings Reaffirms Sell (D-) Rating for Verastem (NASDAQ:VSTM)October 25 at 8:21 PM | marketbeat.comCan Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation?October 24 at 10:49 PM | finance.yahoo.comVerastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS ...October 23 at 11:55 PM | finance.yahoo.comVerastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS ...October 23 at 11:55 PM | finance.yahoo.comVerastem Reports Promising Phase 1/2a Trial DataOctober 23 at 4:51 PM | tipranks.comVerastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?October 23 at 10:56 AM | zacks.comVerastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025October 23 at 8:07 AM | businesswire.comMizuho Securities Reaffirms Their Buy Rating on Verastem (VSTM)October 22, 2025 | theglobeandmail.comVerastem (NASDAQ:VSTM) Upgraded at Zacks ResearchOctober 22, 2025 | marketbeat.comVerastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial UpdateOctober 22, 2025 | finance.yahoo.comBest Momentum Stocks to Buy for Oct. 21October 21, 2025 | zacks.comBuy Rating Affirmed for Verastem’s VS-7375 Due to Promising Efficacy and Competitive Edge in KRAS G12D InhibitorsOctober 21, 2025 | tipranks.comVerastem (NASDAQ:VSTM) Shares Gap Down - What's Next?October 20, 2025 | marketbeat.comAre You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great ChoiceOctober 20, 2025 | zacks.comVerastem Announces Promising Data from VS-7375 StudyOctober 20, 2025 | msn.comWall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a BetOctober 20, 2025 | zacks.comVerastem, Inc. $VSTM is AIGH Capital Management LLC's 10th Largest PositionOctober 20, 2025 | marketbeat.comVerastem FY2025 EPS Forecast Boosted by Cantor FitzgeraldOctober 20, 2025 | americanbankingnews.comVerastem FY2025 EPS Forecast Raised by Cantor FitzgeraldOctober 20, 2025 | marketbeat.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic ...October 19, 2025 | uk.finance.yahoo.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal AdenocarcinomaOctober 19, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesLowe’s vs. Home Depot: Which Benefits More From Lower Rates?By Dan Schmidt | October 8, 2025CoreWeave: Why the New King of AI Infrastructure Has Room to RunBy Jeffrey Neal Johnson | October 1, 2025Why Vertical Aerospace Could Lead the eVTOL Market by 2028By Jeffrey Neal Johnson | September 30, 2025Bloom Energy's Game-Changing AI Deal: Why the Rally Has LegsBy Jeffrey Neal Johnson | October 17, 2025Intel's Turnaround Hits Hyperspeed With A New 52-Week HighBy Jeffrey Neal Johnson | October 17, 2025CFRX, OVID, TYME, VSTM, and ATXI Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.71 +0.00 (+0.03%) As of 10/24/2025 01:56 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.ContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Ovid Therapeutics NASDAQ:OVID$1.63 +0.07 (+4.49%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.62 -0.01 (-0.61%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Tyme Technologies NASDAQ:TYMETyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Verastem NASDAQ:VSTM$7.95 +0.14 (+1.79%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.12 +0.17 (+2.13%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
